Related Experiment Videos
Botulinum toxin A in non-dystonic tremors
J M Henderson1, J A Ghika, G Van Melle
1Policlinique de Neurologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Suisse.
European Neurology
|January 1, 1996
Summary
Botulinum toxin A showed a modest effect on non-dystonic tremors, with 60% of patients improving further after treatment. However, optimizing dosage and injection sites is crucial to minimize side effects like focal weakness.
Area of Science:
- Neurology
- Pharmacology
Background:
- Non-dystonic tremors, including resting, postural, and intention tremors, present a significant challenge in clinical management.
- Botulinum toxin A is increasingly explored for its potential therapeutic effects beyond muscle spasticity.
Purpose of the Study:
- To evaluate the efficacy of botulinum toxin A in treating primarily non-dystonic tremors.
- To assess the tremorolytic effect of botulinum toxin A compared to placebo using accelerometry.
Main Methods:
- A pilot study employed a single-blind, placebo-controlled design.
- Accelerometry was used to measure tremor severity before and after treatment with intramuscular saline or botulinum toxin A (25-50 U).
- Patients were categorized into Parkinson's disease-like (PD-like) and essential tremor-like (ET-like) tremor groups.
Main Results:
- A substantial placebo effect (≥30%) was observed in half of the patients.
- Botulinum toxin A provided further tremor improvement in 60% of patients, exceeding the placebo effect by at least 30%.
- Postural tremor showed significant improvement with botulinum toxin A (40% in PD-like, 57% in ET-like), approximately double the placebo effect. Resting tremor showed minimal additional benefit beyond placebo.
- Nine patients experienced clinically significant focal weakness in extensor muscles, impacting fine motor skills.
Conclusions:
- Botulinum toxin A demonstrates a modest tremorolytic effect for non-dystonic tremors, particularly postural tremor.
- Significant placebo effects necessitate careful interpretation of treatment outcomes.
- Optimizing botulinum toxin A dosage and injection site distribution is essential to maximize therapeutic benefits while minimizing iatrogenic focal weakness.